Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-02-25
    E.g., 2018-02-25

Articles

171624 items
12:35 PM, Feb 23, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Roche reports Phase II data for bispecific DME candidate

Roche (SIX:ROG; OTCQX:RHHBY) reported data from the Phase II BOULEVARD trial to treat diabetic macular edema (DME) showing that once-monthly 6 mg intravitreal RG7716 for 20 weeks met the primary endpoint of improving mean best...
12:35 PM, Feb 23, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Apellis reports 18-month Phase II data for GA candidate

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) reported 18-month data from the Phase II FILLY trial to treat geographic atrophy showing that APL-2 for 12 months maintained significant reductions in lesion growth at six months after stopping treatment....
12:34 PM, Feb 23, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

AbbVie's elagolix meets in Phase III for uterine fibroids

AbbVie Inc. (NYSE:ABBV) said elagolix (ABT-620) met the primary and all ranked secondary endpoints in the Phase III ELARIS UF-I (M12-815) trial to treat uterine fibroids. The trial is the first of two replicate Phase...
12:34 PM, Feb 23, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Akari's Coversin meets in Phase II for PNH

Akari Therapeutics plc (NASDAQ:AKTX) said subcutaneous Coversin met the primary endpoint of reducing lactic dehydrogenase (LDH) to ≤1.8 times the upper limit of normal (ULN) at day 28 in the open-label Phase II COBALT trial...
12:33 PM, Feb 23, 2018  |  BC Week In Review | Company News  |  Deals

Oncologie gains rights to Mologen's lefitolimod

Mologen AG (Xetra:MGN) granted Oncologie Inc. (Boston, Mass.) exclusive, global co-development rights and rights to develop, manufacture and commercialize lefitolimod (MGN1703) in China, Hong Kong, Macao, Taiwan and Singapore. Mologen said the co-development portion of...
12:33 PM, Feb 23, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Celgene reports Phase II data for Otezla in UC

Celgene Corp. (NASAQ:CELG) reported data from a Phase II trial in 170 patients with active ulcerative colitis (UC) showing that twice-daily 30 and 40 mg doses of oral Otezla apremilast (CC-10004) led to clinical remission...
12:33 PM, Feb 23, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Exelixis' cabozantinib meets in Phase II for first-line thyroid cancer

Exelixis Inc. (NASDAQ:EXEL) said once-daily 60 mg oral cabozantinib as first-line treatment met the primary endpoint of objective response rate (ORR) in a Phase II trial to treat metastatic radioiodine-refractory differentiated thyroid cancer. The pre-specified...
12:28 PM, Feb 23, 2018  |  BC Week In Review | Financial News  |  Other Financial News

1315 closes $300M 1315 Capital II fund

1315 Capital LLC (Philadelphia, Pa.) closed its 1315 Capital II fund on Feb. 12 at over $300 million, exceeding its $250 million target. The fund will invest $10-$30 million per company. The company, which has...
12:27 PM, Feb 23, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Avid raises $23M in follow-on

Contract development and manufacturing company Avid Bioservices Inc. (NASDAQ:CDMO) raised $23.2 million through the sale of 10.3 million shares at $2.25 in a follow-on underwritten by Wells Fargo, H.C. Wainwright and Roth. The figures include...
12:27 PM, Feb 23, 2018  |  BC Week In Review | Company News  |  Other News

FDA to hold public workshop on patient experience data guidance

FDA said it will hold a public workshop on March 19 to discuss development of patient-focused drug development guidance as required by the 21st Century Cures Act. The agency is seeking input from multiple stakeholders,...

Pages